Lisinopril
1. Pregnancy Evidence & Regulatory Labeling
FDA Pregnancy and Lactation Labeling Rule (PLLR 8.1) & EMA SmPC Section 4.6
Clinical Risk Summary
FDA Boxed Warning — Fetal Toxicity. Use of drugs that act on the renin-angiotensin system during the 2nd and 3rd trimesters reduces fetal renal function and increases fetal/neonatal morbidity and death (ACE inhibitor fetopathy: oligohydramnios, skull hypoplasia, pulmonary hypoplasia, neonatal renal failure, death). Discontinue immediately upon pregnancy detection.
Human Pregnancy Experience & Clinical Studies
Extensive published literature documents severe fetal renal dysgenesis, anuria, limb contractures, craniofacial deformity, and intrauterine death following 2nd and 3rd trimester exposure.
Animal Reproductive & Developmental Toxicity Data
Animal studies demonstrated reduced maternal blood pressure causing severe uteroplacental hypoperfusion and fetal demise.
Clinical Considerations for Prescribers
When pregnancy is detected, discontinue lisinopril as soon as possible. Switch immediately to pregnancy-compatible antihypertensives (Labetalol, Nifedipine ER, or Methyldopa).
Placental Transfer
Readily crosses the placenta, directly inhibiting fetal renin-angiotensin-aldosterone system.
Regulatory Warnings & Contraindications
FDA Boxed Warning: This medication carries an official Boxed Warning regarding embryo-fetal toxicity or pregnancy-related adverse outcomes.
Contraindicated in pregnancy due to severe fetopathy and mortality risks.
2. Lactation & Breastfeeding Safety
NIH / NLM LactMed® Database & FDA Labeling Section 8.2
Summary of Use during Lactation
Limited data on excretion into human milk. While trace amounts may be present, safer alternatives (Enalapril or Captopril) are preferred during lactation due to better-established safety data.
Drug Levels in Breast Milk & Relative Infant Dose
Very low levels expected; however, infant blood pressure monitoring is prudent.
Effects in Breastfed Infants & Monitored Signs
Risk of neonatal hypotension, particularly in preterm infants.
Effects on Lactation & Milk Production
No known effect on lactation.
Alternate Medications with Established Lactation Data
4. Regulatory Source Provenance & Comparison
Direct attribution to official regulatory documents without synthesized consensus
| Regulatory Organization | Jurisdiction | Document / Framework | Effective Date | Official Source Link |
|---|---|---|---|---|
|
U.S. Food and Drug Administration (FDA)
FDA Prescribing Information (PLLR)
|
United States | regulatory_label | 2026-07-01 | Official Record |
|
National Institutes of Health (NIH) / NLM
LactMed® Database (Drugs and Lactation)
|
United States / Global | evidence_monograph | 2026-08-01 | Official Record |